Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q2 2025 (June 30)5holders +2
2new positions
0sold out
$0.15avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, up 2 from Q1 2025. 2 opened new positions and 0 sold out. The largest holders were Boothbay Fund Management, LLC ($7K), Two Sigma Securities, LLC ($232) and Susquehanna International Group, LLP ($190).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $190 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 21,579 shares bought and 837 shares sold, net +20,742 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $7K |
| Two Sigma Securities, LLC | — | Reduce -0.8% | 13,115 | $232 |
| Susquehanna International Group, LLP | — | New | 10,723 | $190 |
| UBS Group AG | — | Reduce -28.2% | 1,880 | $34 |
| Virtu Financial LLC | — | New | 10,856 | $0 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.